Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 136.88 Delayed Data As of Aug 12 |  +0.08 / +0.06%Today’s Change | 73.32 Today|||52-Week Range 167.33 | +18.85% Year-to-Date |
Latest ALNY News | Press Releases
| Biotech Bonanza - Second Half Outlook Jul 28 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 136.61 |
| Today’s open | 136.32 |
| Day’s range | 135.02 - 139.40 |
| Volume | 391,563 |
| Average volume (3 months) | 778,609 |
| Market cap | $16.6B |
Data as of 3:59pm ET, 08/12/2020
Growth & Valuation
| Earnings growth (last year) | -7.13% |
| Earnings growth (this year) | +21.81% |
| Earnings growth (next 5 years) | -73.99% |
| Revenue growth (last year) | +193.36% |
| P/E ratio | NM |
| Price/Sales | 57.26 |
| Price/Book | 11.18 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | +0.98 | +1.37% |
| CTLTCatalent Inc | -0.09 | -0.10% |
| GLPGGalapagos NV | +4.57 | +2.46% |
| SRPTSarepta Therapeutics... | -0.03 | -0.02% |
Data as of 4:00pm ET, 08/12/2020
Financials
| Next reporting date | October 29, 2020 |
| EPS forecast (this quarter) | -$1.60 |
| Annual revenue (last year) | $219.8M |
| Annual profit (last year) | -$886.1M |
| Net profit margin | -403.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
